Ignite Creation Date:
2024-05-06 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02759419
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2016-04-29
Brief Title:
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
An Open-label Multi-national Multi-center Single-arm Uncontrolled Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension PAH Who Received Riociguat in a Bayer Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RIALTO
Brief Summary:
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521 Riociguat Adempas who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator or commercial availability and reimbursement
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-000501-36 | EUDRACT_NUMBER | None | None |